Proactive Investors - Run By Investors For Investors

Redx Pharma reveals progress on cancer treatments as it reports full year results

Redx Pharma is confident on its 2017 outlook as it develops a pipeline of cancer treatments and restructures the business
RedX expects to achieve £4.2mln in cost savings in its restructuring

Redx Pharma Plc (LON:REDX) said its co-founder, Peter Jackson, and chairman, Frank Armstrong, are stepping down from the board as it reported its full year results.

The drug maker, which began trading on AIM in March 2015, said Jackson will resign at the end of the month while Armstrong has decided not to stand for re-election at the upcoming annual general meeting. 

The announcement came as Redx posted a loss before tax of £15.5mln in the year to 30 September, compared to £8.9mln a year earlier, as the group invested heavily in a pipeline of new products.

Watch: Redx Pharma to refocus on key assets

Its pipeline includes the development of its Porcupine RXC004 treatment for pancreatic, biliary and gastric cancer. 

The drug will enter it first in-human studies following a clinical trial application (CTA) submission in the second quarter.

Redx is also developing leukaemia treatment BTK RXC005 and plans to make an investigational new drug application and CTA towards the end of 2017.

"Redx has created a world-class capability in small molecule drug discovery in oncology and immunology," said chief executive Neil Murray.

"We have a strong research engine that continues to deliver an innovative pipeline, but we must now shift our focus towards developing our key portfolio assets, specifically our Porcupine and BTK programs for hard to treat diseases."

Redx ended the year with net cash of £5.8m, compared to £9.4mln the previous year. The company generated other operating income of £2.4mln, down from the prior year’s £2.6mln, which included fund grants from the Business, Energy and industrial Strategy.

The company said it looks forward to 2017 with confidence to future developments of the business as it transitions from a pre-clinical to a clinical stage and undergoes a restructuring.

As part of the restructuring, the company plans to cut jobs by 60% to 86 positions, which will help achieve cost savings of about £4.2mln. 

View full REDX profile

Redx Pharma Plc Timeline

Related Articles

picture of an affimer
April 03 2017
Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets
Concept of a DNA strand
February 14 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
cancer cells
January 24 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use